The active FAK enhances the chemoresistance of tumor cells against DNA damaging reagents both in vitro and in vivo, suggesting that the TME can affect the response to anticancer therapies and render cancers resistant to treatment [208]. The gene discussed is PTK2; the disease is neoplasm.